Opinion|Videos|July 17, 2024
Factors Driving 3L Therapeutic Selection for mCRC
Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).
Advertisement
Episodes in this series
- Dr Marshall to Panel:Please outline your approach to treatment selection for patients with mCRC in the 3L setting and discuss factors influencing your choice of therapy.
- Dr Cohen: In which patients would you consider fruquintinib versus TAS-102 ± bevacizumab?
- Dr Marshall: For which patients would you deviate from this approach and why you might make this decision?
- Dr Cohen: In which patients would you consider fruquintinib versus TAS-102 ± bevacizumab?
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.
Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
4
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
5